Session Details
[1-MO11]JSNM Oral 11:Drug Discovery and development 4: Miscellaneous
Thu. Nov 19, 2026 3:20 PM - 4:20 PM JST
Thu. Nov 19, 2026 6:20 AM - 7:20 AM UTC
Thu. Nov 19, 2026 6:20 AM - 7:20 AM UTC
Room 9（4F Medium Conference Room 401+402+403）
Chair: Hiroyuki Kimura (Agency for Health, Safety and Environment, Kyoto University), Kohshin Washiyama (Advanced Clinical Research Center, Fukushima Medical University)
[1-MO11-01]Evaluation of 211At-Labeled LAT1-Targeting Amino Acids with an Albumin-Binding Moiety
Hiroaki Echigo1, Masayuki Munekane1, Kenji Mishiro1, Takeshi Fuchigami2, Kohshin Washiyama3, Kazuhiro Takahashi3, Seigo Kinuya4, Kazuma Ogawa1 (1.Graduate School of Medical Sciences, Kanazawa University, Kanazawa, Japan, 2.Graduate School of Engineering, Kyoto University, Kyoto, Japan, 3.Advanced Clinical Research Center, Fukushima Medical University, Fukushima, Japan, 4.Department of Nuclear Medicine, School of Medicine, Kanazawa University, Kanazawa, Japan)
[1-MO11-02]Pharmacological profiling of 64Cu/225Ac-PD-29875 in pancreatic and gastric cancer models
Kentaro Suzuki1, Shota Tsuchida2, Yoshihide Mizukoshi2, Shintaro Kato2, Miho Satake1, Yuki Sato1, Naoki Kanazawa1, Satoshi Matsushima1, Patrick C. Reid2, Masato Murakami1,2, Hidetomo Kitamura2 (1.PDRadiopharma Inc., Chiba, Japan, 2.PeptiDream Inc., Kanagawa, Japan)
[1-MO11-03]Pharmacokinetic modulation of 211At-RGD via albumin-binding inhibition
Sachi Toeda1, Hiroaki Echigo1, Masayuki Munekane1, Takeshi Fuchigami2, Kohshin Washiyama3, Kazuhiro Takahashi3, Kazuma Ogawa1 (1.College of Medical, Pharmaceutical and Health Sciences, Kanazawa University, Kanazawa, Japan, 2.Graduate School of Engineering, Kyoto University, Kyoto, Japan, 3.Advanced Clinical Research Center, Fukushima Medical University, Fukushima, Japan)
[1-MO11-04]Effect of radioiodinated scaffold of a melanoma-targeted probe on in vitro/vivo properties
Ryo Maeta, Toshihide Yamasaki, Kohei Sano, Takahiro Mukai (Department of Pharmacy, Kobe Pharmaceutical University, Hyogo, Japan)
[1-MO11-05]Astatine-211 labeled substrate-type FAP analogs as novel therapeutics targeting FAP alpha
Yoshifumi Shirakami1, Yuichiro Kadonaga1,3, Kazuko Kaneda1,2, Tadashi Watabe1, Sadahiro Naka3, Kazuhiro Ooe1,2, Masashi Murakami1,2, Hiromitsu Haba4, Atsushi Toyoshima1,2 (1.Institute for Radiation Sciences, The University of Osaka, Suita, Japan, 2.MSN Research Project, Forefront Research Center, Graduate School of Science, Osaka University, 3.Department of Pharmacy Osaka University, 4.Nishina Center for Accelerator-Based Science, RIKEN)
[1-MO11-06]Production and quality control testing of the [18F]C05-05 injection for clinical use
Takayuki Ohkubo1,2, Hiroki Hashimoto1, Kaito Tsukagoe1,2, Tomoya Fujishiro1,3, Daisuke Arashi1,3, Tatsuto Sato1,3, Takeru Seki1,3, Masatoshi Muto1,3, Kazunori Kawamura1, Makoto Higuchi1, Ming-Rong Zhang1 (1.Institute for Quantum Medical Science, National Institutes for Quantum Science and Technology, Chiba, Japan, 2.SHI Accelerator Service Ltd., Tokyo, Japan, 3.Tokyo Nuclear Services Co., Ltd., Tokyo, Japan)